

Aurora Science leads the investment in InteRNA Technologies B.V. and continues its portfolio growth

Milan (Italy), Utrecht (The Netherlands), February 9th 2021 – Aurora Science, a biotech investment company resulting from the partnership of Aurora-TT, Rottapharm Biotech and Italfarmaco, announces the growth of the investment portfolio with a transaction to support InteRNA Technologies B.V., a Utrecht-based clinical-stage biotech company specialized in the development of a new generation of miRNA-based products targeting key processes in the initiation and progression of human diseases, with a focus on cancer.

This investment round was led by Aurora Science with support by the Company's existing investors Waterman Ventures and Aglaia Oncology Funds for a Series B financing round amounting to EUR 18.5M in total.

The funding will enable the clinical evaluation of the Company's microRNA lead candidate, INT-1B3, in patients with advanced solid tumors, as well as the further development of other proprietary preclinical drug candidates in its pipeline.

"With this participation in InteRNA Technologies, Aurora Science continues its strong commitment into front-edge science" commented Guido Guidi, Chairman at Aurora Science. "We believe InteRNA has developed a promising innovative technology in this area and look forward to supporting the team on their path forward."

"This successful extension of the Series B financing round validates the unique potential that microRNAs offer as a therapeutic modality for hard-to-treat cancers," said Dr. Roel Schaapveld, CEO of InteRNA Technologies. "We thank Aurora Science and our current investors for their support in bringing our microRNA technology into the clinic and look forward to evaluating INT-1B3's unique mode of action, targeting not only the tumor cells themselves but also the disease-promoting tumor microenvironment."

With an industrial approach, Aurora Science targets highly innovative assets in Europe translating science into care thanks to its know-how from research to product launch.

About Aurora Science

Aurora Science (www.aurorascience.eu) is a biotech investment company integrating an innovative financial and industrial approach coupling expertise and vision of Aurora-TT (www.aurora-tt.com), Rottapharm Biotech (www.rottapharmbiotech.com) and Italfarmaco (www.italfarmaco.com). Aurora Science focuses on the identification and support of cutting-edge start-ups in Europe for the translation of science into care.

About InteRNA Technologies

InteRNA (www.interna-technologies.com) is a Dutch clinical-stage biotech company developing a pipeline of proprietary microRNA (miRNA) therapeutics targeting key processes in initiation and progression of human diseases, with a focus on cancer. Selected through InteRNA's leading miRNA discovery and functional validation platform and enabled with a 3rd generation drug delivery formulation, these miRNA compounds can mount a coordinated anti-cancer attack by engaging multiple signal transduction targets simultaneously.

Media Relations:

Aurora Science srl

Gabriele Campi, Founder and Managing Partner +39 02 9475 8489, gabriele.campi@aurora-tt.com

Edoardo Negroni, Founder and Managing Partner +39 02 9475 8489, edoardo.negroni@aurora-tt.com

Legal advisor: Avv.Valeria Ferrara, Avv.Marco Guidi – Close to Business